The week in health tech, explained in plain English.Get the free newsletter →
October 30, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

Medicaid Fraud Crackdowns Squeeze Care for Disabled

States are tightening Medicaid anti-fraud rules in line with Trump-era policy, and the consequences are landing on people with disabilities who rely on home and community-based care, STAT News reports.

The crackdowns add verification steps and payment scrutiny aimed at rooting out improper billing. In practice, those measures are slowing or stopping reimbursement to the personal-care aides and home caregivers that disabled enrollees depend on. When payments stall, caregivers leave, and clients are left without reliable help for daily tasks. The result is a growing access problem that fraud-prevention rhetoric does not capture.

Medicaid funds the majority of long-term care in the United States, and home-based services are among the most exposed when budgets tighten. As federal pressure pushes states to demonstrate savings and fraud reduction, the administrative burden is shifting onto vulnerable beneficiaries and the workers who serve them, according to STAT News.

Sources

More in Government

Government

Medicare Rule Could Cut Remote Patient Monitoring Access

A proposed CMS rule could sharply reduce Medicare reimbursement for remote patient monitoring, threatening access for rural and chronically ill patients.

Why it matters: Remote monitoring has become a fast-growing, loosely overseen Medicare service, and changing how it pays could reshape home-based care for millions.

Government

HHS Launches National Plan to Overhaul US Kidney Care

HHS launched a national kidney care plan centered on prevention, dialysis reform with more patient choice, and overhauling the transplant system.

Why it matters: Kidney disease affects 1 in 7 US adults and drives major Medicare spending, so federal direction here reshapes care models and markets.

Government

FDA Approves First Once-Weekly Insulin for Children

The FDA approved Novo Nordisk's Awiqli, the first once-weekly basal insulin for children 10 and older with Type 2 diabetes.

Why it matters: Weekly rather than daily insulin could improve adherence for a growing number of children with Type 2 diabetes.